2025
Moderate alcohol-associated hepatitis: A real-world multicenter study
Idalsoaga F, Díaz L, Dunn W, Mehta H, Muñoz K, Caldentey V, Arnold J, Ayares G, Mortuza R, Sarin S, Maiwall R, Zhang W, Qian S, Simonetto D, Singal A, Elfeki M, Ramirez-Cadiz C, Malhi G, Ahmed A, Homsi H, Abid Z, Cabezas J, Echavarría V, Poca M, Soriano G, Cuyas B, Cots M, La Tijera M, Ayala-Valverde M, Perez D, Gomez J, Abraldes J, Al-Karaghouli M, Jalal P, Ibrahim M, García-Tsao G, Goyes D, Skladaný L, Havaj D, Sulejova K, Selcanova S, Rincón D, Chacko K, Restrepo J, Yaquich P, Toro L, Shah V, Arrese M, Kamath P, Bataller R, Arab J. Moderate alcohol-associated hepatitis: A real-world multicenter study. Hepatology Communications 2025, 9: e0673. PMID: 40131003, PMCID: PMC11936654, DOI: 10.1097/hc9.0000000000000673.Peer-Reviewed Original ResearchConceptsSevere alcohol-associated hepatitisNeutrophil-to-lymphocyte ratioMaddrey's discriminant functionModerate AHMultiple organ failureOrgan failureMulticenter retrospective cohort studyAlcohol-associated hepatitisCumulative survival rateRetrospective cohort studyReceiver operating characteristic curveLong-term outcomesShort-term mortalityMortality scoring systemsPrognostic factorsSerum bilirubinMELD scoreWell-characterized diseaseClinical profileMedian MELDCohort studyCox regressionMultivariate analysisTherapeutic strategiesSurvival rateUric Acid Stroke Cerebroprotection Transcended Sex, Age, and Comorbidities in a Multicenter Preclinical Trial
Patel R, Kumskova M, Kodali H, Budnik I, Kuznetsov V, Jain A, Jha A, Thedens D, Dhanesha N, Sutariya B, Nagarkatti K, Lamb J, Kamat P, Shi Y, Avery B, Imai T, Jin X, Chauhan A, Boisserand L, Khan M, Dhandapani K, Sanganahalli B, Sansing L, Hess D, Koehler R, McCullough L, Aronowski J, Ayata C, Diniz M, Lyden P, Planas A, Chamorro A, Chauhan A, Leira E, Investigators O. Uric Acid Stroke Cerebroprotection Transcended Sex, Age, and Comorbidities in a Multicenter Preclinical Trial. Stroke 2025, 56: 965-973. PMID: 40091742, PMCID: PMC11932773, DOI: 10.1161/strokeaha.124.048748.Peer-Reviewed Original ResearchConceptsUA-treated animalsPrimary functional outcomeFunctional outcomesMiddle cerebral artery filament occlusionModified intention-to-treat populationIntention-to-treat populationUric acidHuman clinical trialsImprove functional outcomesStudy drugIntravenous salineEffects of UARelevant to patientsClinical trialsPrimary outcomeSaline controlsSecondary outcomesPreclinical trialsDay 2Survival rateDay 7Filament occlusionGroups of animalsComorbiditiesDiverse comorbiditiesDeterminants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry
Cortellini A, Brunetti L, Di Fazio G, Garbo E, Pinato D, Naidoo J, Katz A, Loza M, Neal J, Genova C, Gettinger S, Kim S, Jayakrishnan R, Zarif T, Russano M, Pecci F, Di Federico A, Awad M, Alessi J, Montrone M, Owen D, Signorelli D, Fidler M, Li M, Camerini A, De Giglio A, Young L, Vincenzi B, Metro G, Passiglia F, Yendamuri S, Guida A, Ghidini M, Awosika N, Napolitano A, Fulgenzi C, Grisanti S, Grossi F, D’Incecco A, Josephides E, Van Hemelrijck M, Russo A, Gelibter A, Spinelli G, Verrico M, Tomasik B, Giusti R, Newsom-Davis T, Bria E, Sebastian M, Rost M, Forster M, Mukherjee U, Landi L, Mazzoni F, Aujayeb A, Dupont M, Curioni-Fontecedro A, Chiari R, Pantano F, Morabito A, Leonetti A, Friedlaender A, Addeo A, Zoratto F, De Tursi M, Cantini L, Roca E, Mountzios G, Della Gravara L, Kalvapudi S, Inno A, Bironzo P, Di Marco Barros R, O’Reilly D, Bell J, Karapanagiotou E, Monnet I, Baena J, Macerelli M, Majem M, Agustoni F, Cortinovis D, Tonini G, Minuti G, Bennati C, Mezquita L, Gorría T, Servetto A, Beninato T, Russo G, Rogado J, Moliner L, Biello F, Nana F, Dingemans A, Aerts J, Ferrara R, Torri V, Abu Hejleh T, Takada K, Naqash A, Garassino M, Peters S, Wakelee H, Nassar A, Ricciuti B. Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry. Journal For ImmunoTherapy Of Cancer 2025, 13: e010674. PMID: 39904562, PMCID: PMC11795382, DOI: 10.1136/jitc-2024-010674.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerAdvanced non-small cell lung cancerProgrammed cell death ligand 1Eastern Cooperative Oncology Group performance statusData cut-offLong-term efficacyIndividual patient-level dataMedian OSPembrolizumab monotherapySurvival rateProgressive diseaseDiscontinued treatment due to progressive diseaseTreated with first-line pembrolizumabClinical trialsPredictors of 5-year survivalFirst-line pembrolizumab monotherapyCell death ligand 1Pre-existing autoimmune diseaseFirst-line pembrolizumabKEYNOTE-024 trialPD-L1 TPSPermanently discontinue treatmentDeath-ligand 1Efficacy of pembrolizumabMedian follow-up
2024
Prediction of neonatal survival among Pacific Islander preterm births in the US
Wu B, Taylor S, Shabanova V, Hawley N. Prediction of neonatal survival among Pacific Islander preterm births in the US. PLOS ONE 2024, 19: e0316048. PMID: 39739767, PMCID: PMC11687717, DOI: 10.1371/journal.pone.0316048.Peer-Reviewed Original ResearchConceptsGestational ageNeonatal sexBirth weightNeonatal mortalityNeonatal survivalPreterm birthBorn large-for-gestational ageLarge-for-gestational ageObesity-related risk factorsPrediction of neonatal survivalPre-pregnancy obesityGroup of neonatesMortality rateNeonatal mortality rateUnited States National Center for Health StatisticsDeath data filesPacific Islander mothersPredicted survival ratesGestational weeksPre-pregnancyNeonatal deathCongenital anomaliesGestationSurvival rateRisk factorsRhabdomyolysis in Severe Fever With Thrombocytopenia Syndrome: Associations With Acute Kidney Injury and Mortality
Zhang Z, Hu X, Du Q, Liu J, Chen X, Mo P, Luo M, Jiang Q, Deng L, Xiong Y. Rhabdomyolysis in Severe Fever With Thrombocytopenia Syndrome: Associations With Acute Kidney Injury and Mortality. Journal Of Medical Virology 2024, 96: e70095. PMID: 39624019, DOI: 10.1002/jmv.70095.Peer-Reviewed Original ResearchConceptsAcute kidney injuryKidney injuryRhabdomyolysis groupLaboratory parametersClinical characteristicsLevels of laboratory parametersThrombocytopenia syndromeMultivariate binary logistic regression analysisCumulative survival rateHigh viral loadMortality of patientsSevere feverBinary logistic regression analysisLogistic regression analysisAbdominal painConsecutive patientsSFTS patientsSerum levelsViral loadChest distressAdverse outcomesRhabdomyolysisSurvival ratePatientsSystem injuryHMA/VEN treatment modifications and associated outcomes in IDH-mutant AML
Chin K, Derkach A, Famulare C, Gupta G, Borge P, Geyer M, Goldberg A, Haque T, Park J, Roeker L, Tallman M, Stahl M, Stein E. HMA/VEN treatment modifications and associated outcomes in IDH-mutant AML. Leukemia & Lymphoma 2024, 66: 270-278. PMID: 39397429, DOI: 10.1080/10428194.2024.2411436.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaTreatment modificationHypomethylating agentsResponse rateAssociated with lower response ratesMedian overall survivalIDH-mutated acute myeloid leukemiaLong-term toxicityCR/CRi rateSignificant neutropeniaFebrile neutropeniaInduction chemotherapyOverall survivalMyeloid leukemiaLow response rateSurvival rateAffect survivalNeutropeniaVenetoclaxSurvivalED visitsPatientsR/RMonthsReal-world settingsA Survival Analysis of Patients with Radiation-Induced Cancers after Prior Radiation for Head and Neck Cancer
Laseinde E, Guan L, Hildebrand R, Meurice N, Gensheimer M, Beadle B, Holsinger F, Sunwoo J, Baik F, Sirjani D, Divi V, Kaplan M, Pinto H, Colevas A, Rahman M, Le Q. A Survival Analysis of Patients with Radiation-Induced Cancers after Prior Radiation for Head and Neck Cancer. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: e764. DOI: 10.1016/j.ijrobp.2024.07.1678.Peer-Reviewed Original ResearchHead and neck cancerNonsurgical groupNeck cancerRadiation treatmentTreated with non-surgical therapyIRB-approved retrospective reviewSurvival rateKaplan-Meier survival curvesSurvival rate of patientsNon-surgical therapySurvival analysis of patientsLog-rank testAnalysis of patientsNon-surgical groupNon-surgical treatmentRate of patientsRadiation-induced cancerCompare survival ratesPrior RTPostoperative RTMedian followPrior radiationSquamous histologyOverall survivalMedian ageRobotic-Assisted Microsurgery in Lymphatic Reconstruction
Stögner V, Pucciarelli D, Pomahac B, Ayyala H. Robotic-Assisted Microsurgery in Lymphatic Reconstruction. Journal Of Craniofacial Surgery 2024, 36: 359-362. PMID: 39283135, DOI: 10.1097/scs.0000000000010608.Peer-Reviewed Original ResearchLymphatic reconstructionRobotic-assisted microsurgeryBreast cancer-related lymphedemaCancer-related lymphedemaSurgical outcomesYears of clinical experienceMicrosurgical reconstructionPatient groupLymphatic flowCancer incidenceSurvival rateLymphatic anastomosisMicrosurgical performanceClinical experienceMicrosurgeryLower extremitiesHuman vesselsLymphatic microsurgeryPatientsMicrosurgical robotPhysiological tremorAn unusual case of primary melioidotic prostatic disease: Misdiagnosed as benign prostatic hyperplasia
Cai Y, Jiang H, Li T, Luo D, Li P, Wang Y. An unusual case of primary melioidotic prostatic disease: Misdiagnosed as benign prostatic hyperplasia. Heliyon 2024, 10: e37906. PMID: 39323819, PMCID: PMC11422042, DOI: 10.1016/j.heliyon.2024.e37906.Peer-Reviewed Original ResearchBenign prostatic hyperplasiaProstate diseaseProstatic hyperplasiaBurkholderia pseudomallei</i>.Urine culturePulmonary infectionTrimethoprim-sulfamethoxazoleSurvival rate of patientsTreated with imipenemUrinary tract infectionAnti-infective treatmentRate of patientsHistory of hypertensionYear old maleMultiple organ damageProstatic abscessTract infectionsInflammatory markersClinical manifestationsCure rateUnusual caseFatal infectious diseaseOrgan damageDifficulty urinatingSurvival rateCTHRC1+ fibroblasts and SPP1+ macrophages synergistically contribute to pro-tumorigenic tumor microenvironment in pancreatic ductal adenocarcinoma
Li E, Cheung H, Ma S. CTHRC1+ fibroblasts and SPP1+ macrophages synergistically contribute to pro-tumorigenic tumor microenvironment in pancreatic ductal adenocarcinoma. Scientific Reports 2024, 14: 17412. PMID: 39075108, PMCID: PMC11286765, DOI: 10.1038/s41598-024-68109-z.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaTumor-associated macrophagesTumor microenvironmentEpithelial mesenchymal transitionDuctal adenocarcinomaImmune-suppressive tumor microenvironmentPro-tumorigenic tumor microenvironmentPancreatic cancer casesHeterogeneous tumor microenvironmentCombination of single-cellCancer-associated myofibroblastsSurgical resectionMyeloid cellsCurrent therapiesCancer casesLethal cancersSurvival rateExtracellular matrixTreat cancerMesenchymal transitionTherapeutic targetAdenocarcinomaCellular populationsCancerIntercellular interactionsInterstitial Lung Diseases and Non-Small Cell Lung Cancer: Particularities in Pathogenesis and Expression of Driver Mutations
Sampsonas F, Bosgana P, Bravou V, Tzouvelekis A, Dimitrakopoulos F, Kokkotou E. Interstitial Lung Diseases and Non-Small Cell Lung Cancer: Particularities in Pathogenesis and Expression of Driver Mutations. Genes 2024, 15: 934. PMID: 39062713, PMCID: PMC11276289, DOI: 10.3390/genes15070934.Peer-Reviewed Original ResearchConceptsInterstitial lung diseaseLung cancerLung diseaseDriver mutationsImproved survivalTreatment optionsChronic inflammationPathogenetic pathwaysNon-small cell lung cancerConcurrent interstitial lung diseaseCell lung cancerSites of chronic inflammationAnti-fibrotic medicationsCurrent treatment optionsIdiopathic pulmonary fibrosisDiseases associated with chronic inflammationIncidence of lung cancerPersonalized medicine approachPrompt diagnosisClinical entityNon-smallPulmonary fibrosisNSCLCSurvival ratePatientsMaximizing Donor Egg Efficiency: Artificial Intelligence and Genetically Certified Oocytes
Aydin B, Hudkova D, Halicigil C. Maximizing Donor Egg Efficiency: Artificial Intelligence and Genetically Certified Oocytes. 2024, 471-490. DOI: 10.1007/978-3-031-58214-1_48.Peer-Reviewed Original ResearchDonor oocyte banksSelection of oocytesOocyte bankingOocyte vitrificationOocyte donationPGT-A methodsChances of implantationVitrification protocolPolar body biopsyUsable blastocystsEuploid blastocystsPGT-AAneuploid oocytesClinical pregnancyBody biopsyAneuploidy statusBiopsy methodClinical dataOncological problemSurvival rateOocytesPolar bodyPatientsMorphological evaluationMedical reasonsPredictive modeling of gene mutations for the survival outcomes of epithelial ovarian cancer patients
C. M, Lavi E, Altwerger G, Lin Z, Ratner E. Predictive modeling of gene mutations for the survival outcomes of epithelial ovarian cancer patients. PLOS ONE 2024, 19: e0305273. PMID: 38976671, PMCID: PMC11230535, DOI: 10.1371/journal.pone.0305273.Peer-Reviewed Original ResearchConceptsEpithelial ovarian cancerEpithelial ovarian cancer patientsEpithelial ovarian cancer casesGene mutation signaturesPlatinum-based chemotherapyThe Cancer Genome AtlasResponse to treatmentOverall survivalGene mutationsMutational signaturesHomologous recombinationSurvival outcomesIncreased sensitivity to platinum-based chemotherapySensitivity to platinum-based chemotherapyAssociated with increased chemoresistanceResistance to platinum-based chemotherapySurvival timeSurvival rateFavorable response to treatmentPlatinum-induced DNA damageKaplan-Meier survival analysisPrediction of survival outcomesOvarian cancer patientsOverall survival ratePrediction of treatment outcomeNCF4 attenuates colorectal cancer progression by modulating inflammasome activation and immune surveillance
Li L, Mao R, Yuan S, Xie Q, Meng J, Gu Y, Tan S, Xu X, Gao C, Liu H, Ma C, Man S, Meng X, Xu T, Qi X. NCF4 attenuates colorectal cancer progression by modulating inflammasome activation and immune surveillance. Nature Communications 2024, 15: 5170. PMID: 38886341, PMCID: PMC11183137, DOI: 10.1038/s41467-024-49549-7.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCARD Signaling Adaptor ProteinsCD8-Positive T-LymphocytesCell Line, TumorColorectal NeoplasmsDisease ProgressionFemaleHumansImmunologic SurveillanceInflammasomesInterleukin-18Killer Cells, NaturalMaleMiceMice, Inbred C57BLMice, KnockoutNADPH OxidasesNLR Family, Pyrin Domain-Containing 3 ProteinPhosphorylationReactive Oxygen SpeciesConceptsInflammasome activationColorectal cancerFive-year survival rateAssociated with colorectal cancer developmentAnti-tumor responsesCD8+ TColorectal cancer developmentColorectal cancer progressionApoptosis-associated speck-like proteinNK cellsImmune surveillanceRegulation of inflammasome activationSpeck-like proteinCancer developmentSurvival rateCancer progressionColorectal tumorigenesisPrecancerous cellsTransit amplifyingAIM2 inflammasome activationImmunoprecipitation-mass spectrometry analysisInflammasome responsesNCF4Modulating inflammasome activationROS levelsHigh-throughput assays to assess variant effects on disease
Ma K, Gauthier L, Cheung F, Huang S, Lek M. High-throughput assays to assess variant effects on disease. Disease Models & Mechanisms 2024, 17: dmm050573. PMID: 38940340, PMCID: PMC11225591, DOI: 10.1242/dmm.050573.Peer-Reviewed Original ResearchConceptsDeep mutational scanningGenetic variantsRare disease diagnosticsRare genetic variantsDisease mechanismsHigh-throughput assaySequencing effortsInvestigation of variantsMutational scanningModel cell lineVariant effectsMolecular toolsCell linesCell survival rateFunctional assaysDrug resistanceDisease diagnosticsDisease-relevant assaysVariantsClinical case reportBiological mechanismsAssayCase reportClinical reportsSurvival rateFunctional Mitral Valve Regurgitation: Mitral Valve Repair or Replacement? Our “Road Map” for the Appropriate Strategy
Sideris K, Burri M, Mayr A, Voss S, Vitanova K, Prinzing A, Voss B, Amabile A, Geirsson A, Krane M, Guenzinger R. Functional Mitral Valve Regurgitation: Mitral Valve Repair or Replacement? Our “Road Map” for the Appropriate Strategy. Journal Of Clinical Medicine 2024, 13: 3264. PMID: 38892978, PMCID: PMC11172680, DOI: 10.3390/jcm13113264.Peer-Reviewed Original ResearchFunctional mitral regurgitationPoor ejection fractionSurgical approachMV replacementMV repairEjection fractionAtrial fibrillationMitral valve (MV) surgeryEtiology of functional mitral regurgitationDilatation of left ventricleTreatment of functional mitral regurgitationSurvival ratePresence of atrial fibrillationSevere LV dilatationMitral valve replacementOverall survival rateOptimal surgical approachRisk of deathYears of ageLV dilatationMitral regurgitationLV functionPostoperative survivalValve replacementLV dimensionsImmune checkpoint inhibitors in high‐grade upper tract urothelial carcinoma: Paradigm shift emphasizing organ preservation
Khalil M, Fishman A, Komorowski A, Franco I, Grasso M. Immune checkpoint inhibitors in high‐grade upper tract urothelial carcinoma: Paradigm shift emphasizing organ preservation. BJUI Compass 2024, 5: 604-610. PMID: 38751949, PMCID: PMC11090768, DOI: 10.1002/bco2.335.Peer-Reviewed Original ResearchImmune check point inhibitorsHigh-grade upper tract urothelial carcinomaUpper tract urothelial carcinomaMetastasis-free survival ratesGroup 2Group 1Survival rateUrothelial carcinomaSurvival outcomesMedian follow-up periodImpact of clinical characteristicsCheck-point inhibitorsImmune checkpoint inhibitorsEndoscopically treated patientsInitial tumor sizeImprove survival outcomesOverall survival rateKaplan-Meier analysisFollow-up periodImproved survival ratesCheckpoint inhibitorsPoint inhibitorsExtirpative surgeryTumor sizeClinical characteristicsSerum aryl hydrocarbon receptor activity is associated with survival in patients with alcohol-associated hepatitis
Yamazaki T, Kouno T, Hsu C, Hartmann P, Mayo S, Zhang X, Stärkel P, Bosques-Padilla F, Verna E, Abraldes J, Brown R, Vargas V, Altamirano J, Caballería J, Shawcross D, Louvet A, Lucey M, Mathurin P, Garcia-Tsao G, Bataller R, Investigators A, Schnabl B. Serum aryl hydrocarbon receptor activity is associated with survival in patients with alcohol-associated hepatitis. Hepatology 2024, 80: 403-417. PMID: 38377466, DOI: 10.1097/hep.0000000000000777.Peer-Reviewed Original ResearchAlcohol-associated hepatitisAlcohol use disorderSevere AHAH patientsAhR activationMicrobiota-derived tryptophan metabolitesSurvival rateAssociated with high mortalityCumulative survival rateAssociated with survivalAryl hydrocarbon receptor activationMulticenter cohortFecal metabolomePrognostic markerTryptophan metabolitesReceptor activationAryl hydrocarbon receptorPatientsUse disorderAH cohortSerumHigher mortalityAhRHepatitisCohortP-19 CHARACTERIZATION, PROGNOSTIC FACTORS, AND SURVIVAL IN MODERATE ALCOHOL-ASSOCIATED HEPATITIS: A MULTICENTER STUDY
Idalsoaga F, Díaz L, Corsi O, Ayares G, Arnold J, Dunn W, Li Y, Singal A, Simonetto D, Ayala-Valverde M, Ramirez C, Morales-Arraez D, Zhang W, Qian S, Ahn J, Buryska S, Mehta H, Waleed M, Stefanescu H, Horhat A, Bumbu A, Attar B, Agrawal R, Cabezas J, Cuyàs B, Poca M, Pastor G, Sarin S, Maiwall R, Jalal P, La Tijera M, Kulkarni A, Rao N, Salazar P, Skladaný L, Bystrianska N, Prado V, Clemente-Sanchez A, Rincón D, Haider T, Chacko K, Romero G, Pollarsky F, Restrepo J, Toro L, Yaquich P, Mendizabal M, Garrido M, Marciano S, Dirchwolf M, Vargas V, Jimenez C, García-Tsao G, Ortiz G, Abraldes J, Kamath P, Shah V, Bataller R, Arab J. P-19 CHARACTERIZATION, PROGNOSTIC FACTORS, AND SURVIVAL IN MODERATE ALCOHOL-ASSOCIATED HEPATITIS: A MULTICENTER STUDY. Annals Of Hepatology 2024, 29: 101206. DOI: 10.1016/j.aohep.2023.101206.Peer-Reviewed Original ResearchRenal replacement therapyVariables associated with mortalityModerate AHAlcohol-associated hepatitisPrognostic factorsLiver transplantationMaddrey's discriminant functionAssociated with high mortalityMultiple organ failureRetrospective cohort studyMultivariate-adjusted modelsShort-term mortalityAssociated with mortalityCompeting-risks modelMedian ageCause of deathReplacement therapyMulticenter studyMELD scoreOrgan failureUnivariate analysisCohort studyFrequent causeSevere entitySurvival rateExtremely Long-Term Follow-Up of Dr William Glenn's Original Patient Cohort With Superior Cavopulmonary Anastomosis (1958-1990)
Lee M, Amabile A, Geirsson A, Gruber P, Kopf G. Extremely Long-Term Follow-Up of Dr William Glenn's Original Patient Cohort With Superior Cavopulmonary Anastomosis (1958-1990). World Journal For Pediatric And Congenital Heart Surgery 2024, 15: 298-302. PMID: 38263670, DOI: 10.1177/21501351231224342.Peer-Reviewed Original ResearchSuperior cavopulmonary anastomosisFollow-upGlenn operationCavopulmonary anastomosisRetrospective evaluation of patientsLost to follow-upAdult congenital patientsTetralogy of FallotYears of follow-upOriginal patient cohortEvaluation of patientsGroup of patientsFollow-up dataGlenn patientsCongenital patientsPalliative procedureSurviving patientsPediatric patientsAge of survivorsPatient cohortRetrospective evaluationSurvival ratePatientsMedical recordsElectronic medical records
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply